Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug candidate BL-M02D1 enters human trials for Hard-to-Treat cancers

NCT ID NCT05339685

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called BL-M02D1 in people with advanced triple negative breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 82 participants will take part in two stages to determine the best dose for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm digestive system neoplasm neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510120, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Jilin University

    Changchun, Jilin, China

  • The Second Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China

  • Yueyang People's Hospital

    Yueyang, Hunan, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.